{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:41:41Z","timestamp":1794282101439,"version":"4.9.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["MutaEB"],"award-info":[{"award-number":["MutaEB"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40291-020-00466-7","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T11:03:41Z","timestamp":1587639821000},"page":"299-309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-507X","authenticated-orcid":false,"given":"Cristina","family":"Has","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"South","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouni","family":"Uitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"466_CR1","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","volume":"70","author":"J-D Fine","year":"2014","unstructured":"Fine J-D, Bruckner-Tuderman L, Eady RAJ, Bauer EA, Bauer JW, Has C, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70:1103\u201326.","journal-title":"J Am Acad Dermatol"},{"key":"466_CR2","doi-asserted-by":"crossref","unstructured":"Has C, Bauer JW, Bodemer C, Bolling M, Bruckner-Tuderman L, Diem A, et al. Consensus re-classification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020.","DOI":"10.1111\/bjd.18921"},{"key":"466_CR3","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jid.2017.12.016","volume":"138","author":"J Uitto","year":"2018","unstructured":"Uitto J, Bruckner-Tuderman L, McGrath JA, Riedl R, Robinson C. EB2017-progress in epidermolysis bullosa research toward treatment and cure. J Invest Dermatol. 2018;138:1010\u20136.","journal-title":"J Invest Dermatol."},{"key":"466_CR4","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/bjd.13945","volume":"173","author":"A Schwieger-Briel","year":"2015","unstructured":"Schwieger-Briel A, Weibel L, Chmel N, Leppert J, Kernland-Lang K, Gr\u00fcninger G, et al. A COL7A1 variant leading to in-frame skipping of exon 15 attenuates disease severity in recessive dystrophic epidermolysis bullosa. Br J Dermatol. 2015;173:1308\u201311.","journal-title":"Br J Dermatol"},{"key":"466_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/jmg.2010.086751","volume":"48","author":"D Kiritsi","year":"2011","unstructured":"Kiritsi D, Kern JS, Schumann H, Kohlhase J, Has C, Bruckner-Tuderman L. Molecular mechanisms of phenotypic variability in junctional epidermolysis bullosa. J Med Genet. 2011;48:450\u20137.","journal-title":"J Med Genet"},{"key":"466_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1046\/j.1365-2133.1998.02515.x","volume":"139","author":"JE Mellerio","year":"1998","unstructured":"Mellerio JE, Pulkkinen L, McMillan JR, Lake BD, Horn HM, Tidman MJ, et al. Pyloric atresia-junctional epidermolysis bullosa syndrome: mutations in the integrin beta4 gene (ITGB4) in two unrelated patients with mild disease. Br J Dermatol. 1998;139:862\u201371.","journal-title":"Br J Dermatol"},{"key":"466_CR7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2340\/00015555-3133","volume":"99","author":"J Hoffmann","year":"2019","unstructured":"Hoffmann J, Casetti F, Reimer A, Leppert J, Gr\u00fcninger G, Has C. A silent COL17A1 variant alters splicing and causes junctional epidermolysis bullosa. Acta Derm Venereol. 2019;99:460\u20131.","journal-title":"Acta Derm Venereol"},{"key":"466_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/humu.20647","volume":"29","author":"M Titeux","year":"2008","unstructured":"Titeux M, Pendaries V, Tonasso L, Decha A, Bodemer C, Hovnanian A. A frequent functional SNP in the MMP1 promoter is associated with higher disease severity in recessive dystrophic epidermolysis bullosa. Hum Mutat. 2008;29:267\u201376.","journal-title":"Hum Mutat"},{"key":"466_CR9","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1093\/hmg\/ddu102","volume":"23","author":"T Odorisio","year":"2014","unstructured":"Odorisio T, Di Salvio M, Orecchia A, Di Zenzo G, Piccinni E, Cianfarani F, et al. Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-\u03b2 signalling in modifying disease severity. Hum Mol Genet. 2014;23:3907\u201322.","journal-title":"Hum Mol Genet"},{"key":"466_CR10","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/humu.23592","volume":"39","author":"H Vahidnezhad","year":"2018","unstructured":"Vahidnezhad H, Youssefian L, Saeidian AH, Touati A, Sotoudeh S, Jazayeri A, et al. Next generation sequencing identifies double homozygous mutations in two distinct genes (EXPH5 and COL17A1) in a patient with concomitant simplex and junctional epidermolysis bullosa. Hum Mutat. 2018;39:1349\u201354.","journal-title":"Hum Mutat"},{"key":"466_CR11","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/humu.23980","volume":"41","author":"H Vahidnezhad","year":"2020","unstructured":"Vahidnezhad H, Youssefian L, Sotoudeh S, Liu L, Guy A, Lovell PA, et al. Genomics-based treatment in a patient with two overlapping heritable skin disorders: Epidermolysis bullosa and acrodermatitis enteropathica. Hum Mutat. 2020;41:906\u201312.","journal-title":"Hum Mutat."},{"key":"466_CR12","doi-asserted-by":"publisher","first-page":"108228","DOI":"10.1016\/j.clim.2019.06.004","volume":"208","author":"ME Maccari","year":"2019","unstructured":"Maccari ME, Speckmann C, Heeg M, Reimer A, Casetti F, Has C, et al. Profound immunodeficiency with severe skin disease explained by concomitant novel CARMIL2 and PLEC1 loss-of-function mutations. Clin Immunol Orlando Fla. 2019;208:108228.","journal-title":"Clin Immunol Orlando Fla."},{"key":"466_CR13","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/jid.2013.31","volume":"133","author":"V Wally","year":"2013","unstructured":"Wally V, Lettner T, Peking P, Peckl-Schmid D, Murauer EM, Hainzl S, et al. The pathogenetic role of IL-1\u03b2 in severe epidermolysis bullosa simplex. J Invest Dermatol. 2013;133:1901\u20133.","journal-title":"J Invest Dermatol."},{"key":"466_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/bjd.17698","volume":"181","author":"E Chac\u00f3n-Solano","year":"2019","unstructured":"Chac\u00f3n-Solano E, Le\u00f3n C, D\u00edaz F, Garc\u00eda-Garc\u00eda F, Garc\u00eda M, Esc\u00e1mez MJ, et al. Fibroblasts activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses. Br J Dermatol. 2019;181:512\u201322.","journal-title":"Br J Dermatol."},{"key":"466_CR15","doi-asserted-by":"publisher","first-page":"e1528","DOI":"10.1097\/MD.0000000000001528","volume":"94","author":"G Annicchiarico","year":"2015","unstructured":"Annicchiarico G, Morgese MG, Esposito S, Lopalco G, Lattarulo M, Tampoia M, et al. Proinflammatory cytokines and antiskin autoantibodies in patients with inherited epidermolysis bullosa. Medicine (Baltimore). 2015;94:e1528.","journal-title":"Medicine (Baltimore)."},{"key":"466_CR16","doi-asserted-by":"crossref","unstructured":"Reimer A, Hess M, Schwieger-Briel A, Kiritsi D, Schauer F, Schumann H, et al. Natural history of growth and anaemia in children with epidermolysis bullosa: a retrospective cohort study. Br J Dermatol. 2019.","DOI":"10.1111\/bjd.19068"},{"key":"466_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2008.09.035","volume":"60","author":"JD Fine","year":"2009","unstructured":"Fine JD, Johnson LB, Weiner M, Li KP, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. J Am Acad Dermatol. 2009;60:203\u201311.","journal-title":"J Am Acad Dermatol"},{"key":"466_CR18","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/humu.21576","volume":"32","author":"C Has","year":"2011","unstructured":"Has C, Castiglia D, del Rio M, Diez MG, Piccinni E, Kiritsi D, et al. Kindler syndrome: extension of FERMT1 mutational spectrum and natural history. Hum Mutat. 2011;32:1204\u201312.","journal-title":"Hum Mutat"},{"key":"466_CR19","first-page":"338","volume":"16","author":"M Saleva","year":"2018","unstructured":"Saleva M, Has C, He Y, Vassileva S, Balabanova M, Miteva L. Natural history of Kindler syndrome and propensity for skin cancer\u2014case report and literature review. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2018;16:338\u201341.","journal-title":"J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG."},{"key":"466_CR20","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1038\/mt.2014.140","volume":"22","author":"J Cogan","year":"2014","unstructured":"Cogan J, Weinstein J, Wang X, Hou Y, Martin S, South AP, et al. Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa. Mol Ther J Am Soc Gene Ther. 2014;22:1741\u201352.","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"466_CR21","doi-asserted-by":"publisher","first-page":"E6536","DOI":"10.1073\/pnas.1803154115","volume":"115","author":"V Lincoln","year":"2018","unstructured":"Lincoln V, Cogan J, Hou Y, Hirsch M, Hao M, Alexeev V, et al. Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa. Proc Natl Acad Sci USA. 2018;115:E6536\u201345.","journal-title":"Proc Natl Acad Sci USA"},{"key":"466_CR22","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1172\/JCI92707","volume":"127","author":"DT Woodley","year":"2017","unstructured":"Woodley DT, Cogan J, Hou Y, Lyu C, Marinkovich MP, Keene D, et al. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients. J Clin Invest. 2017;127:3028\u201338.","journal-title":"J Clin Invest."},{"key":"466_CR23","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.jid.2017.05.011","volume":"137","author":"VS Atanasova","year":"2017","unstructured":"Atanasova VS, Jiang Q, Prisco M, Gruber C, Pi\u00f1\u00f3n Hofbauer J, Chen M, et al. Amlexanox enhances premature termination codon read-through in COL7A1 and expression of full length type VII Collagen: potential therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2017;137:1842\u20139.","journal-title":"J Invest Dermatol."},{"key":"466_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/exd.13141","volume":"26","author":"O Bornert","year":"2017","unstructured":"Bornert O, Peking P, Bremer J, Koller U, van den Akker PC, Aartsma-Rus A, et al. RNA-based therapies for genodermatoses. Exp Dermatol. 2017;26:3\u201310.","journal-title":"Exp Dermatol"},{"key":"466_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bjd.17075","volume":"180","author":"P Peking","year":"2019","unstructured":"Peking P, Breitenbach JS, Ablinger M, Muss WH, Poetschke FJ, Kocher T, et al. An ex\u00a0vivo RNA trans-splicing strategy to correct human generalized severe epidermolysis bullosa simplex. Br J Dermatol. 2019;180:141\u20138.","journal-title":"Br J Dermatol"},{"key":"466_CR26","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1016\/j.ymthe.2017.08.015","volume":"25","author":"T Kocher","year":"2017","unstructured":"Kocher T, Peking P, Klausegger A, Murauer EM, Hofbauer JP, Wally V, et al. Cut and paste: efficient homology-directed repair of a dominant negative KRT14 mutation via CRISPR\/Cas9 nickases. Mol Ther J Am Soc Gene Ther. 2017;25:2585\u201398.","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"466_CR27","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jid.2018.11.036","volume":"139","author":"MP Marinkovich","year":"2019","unstructured":"Marinkovich MP, Tang JY. Gene therapy for epidermolysis bullosa. J Invest Dermatol. 2019;139:1221\u20136.","journal-title":"J Invest Dermatol."},{"key":"466_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5582\/irdr.2017.01005","volume":"6","author":"E Rashidghamat","year":"2017","unstructured":"Rashidghamat E, McGrath JA. Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa. Intractable Rare Dis Res. 2017;6:6\u201320.","journal-title":"Intractable Rare Dis Res."},{"key":"466_CR29","doi-asserted-by":"publisher","first-page":"e130554","DOI":"10.1172\/jci.insight.130554","volume":"4","author":"S Eichstadt","year":"2019","unstructured":"Eichstadt S, Barriga M, Ponakala A, Teng C, Nguyen NT, Siprashvili Z, et al. Phase 1\/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa. JCI Insight. 2019;4:e130554.","journal-title":"JCI Insight."},{"key":"466_CR30","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1001\/jama.2016.15588","volume":"316","author":"Z Siprashvili","year":"2016","unstructured":"Siprashvili Z, Nguyen NT, Gorell ES, Loutit K, Khuu P, Furukawa LK, et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. JAMA. 2016;316:1808\u201317.","journal-title":"JAMA"},{"key":"466_CR31","doi-asserted-by":"publisher","first-page":"4356","DOI":"10.1073\/pnas.95.8.4356","volume":"95","author":"TM Kolodka","year":"1998","unstructured":"Kolodka TM, Garlick JA, Taichman LB. Evidence for keratinocyte stem cells in vitro: long term engraftment and persistence of transgene expression from retrovirus-transduced keratinocytes. Proc Natl Acad Sci USA. 1998;95:4356\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"key":"466_CR32","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1177\/0963689719857657","volume":"28","author":"DM Supp","year":"2019","unstructured":"Supp DM, Hahn JM, Combs KA, McFarland KL, Schwentker A, Boissy RE, et al. Collagen VII expression is required in both keratinocytes and fibroblasts for anchoring fibril formation in bilayer engineered skin substitutes. Cell Transpl. 2019;28:1242\u201356.","journal-title":"Cell Transpl"},{"key":"466_CR33","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/bjd.18559","volume":"182","author":"S Gaucher","year":"2020","unstructured":"Gaucher S, Lwin SM, Titeux M, Abdul-Wahab A, Pironon N, Izmiryan A, et al. EBGene trial: patient preselection outcomes for the European GENEGRAFT ex\u00a0vivo phase I\/II gene therapy trial for recessive dystrophic epidermolysis bullosa. Br J Dermatol. 2020;182:794\u20137.","journal-title":"Br J Dermatol"},{"key":"466_CR34","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/nm1504","volume":"12","author":"F Mavilio","year":"2006","unstructured":"Mavilio F, Pellegrini G, Ferrari S, Di Nunzio F, Di Iorio E, Recchia A, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med. 2006;12:1397\u2013402.","journal-title":"Nat Med"},{"key":"466_CR35","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jid.2016.10.038","volume":"137","author":"JW Bauer","year":"2017","unstructured":"Bauer JW, Koller J, Murauer EM, De Rosa L, Enzo E, Carulli S, et al. Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells. J Invest Dermatol. 2017;137:778\u201381.","journal-title":"J Invest Dermatol."},{"key":"466_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature24487","volume":"551","author":"T Hirsch","year":"2017","unstructured":"Hirsch T, Rothoeft T, Teig N, Bauer JW, Pellegrini G, De Rosa L, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature. 2017;551:327\u201332.","journal-title":"Nature"},{"key":"466_CR37","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41586-019-1085-7","volume":"568","author":"N Liu","year":"2019","unstructured":"Liu N, Matsumura H, Kato T, Ichinose S, Takada A, Namiki T, et al. Stem cell competition orchestrates skin homeostasis and ageing. Nature. 2019;568:344\u201350.","journal-title":"Nature"},{"issue":"2036\u20132049","key":"466_CR38","first-page":"e6","volume":"27","author":"L De Rosa","year":"2019","unstructured":"De Rosa L, Secone Seconetti A, De Santis G, Pellacani G, Hirsch T, Rothoeft T, et al. Laminin 332-dependent YAP dysregulation depletes epidermal stem cells in junctional epidermolysis bullosa. Cell Rep. 2019;27(2036\u20132049):e6.","journal-title":"Cell Rep."},{"key":"466_CR39","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ymthe.2019.03.007","volume":"27","author":"J Bonafont","year":"2019","unstructured":"Bonafont J, Menc\u00eda \u00c1, Garc\u00eda M, Torres R, Rodr\u00edguez S, Carretero M, et al. Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR\/Cas9-mediated gene editing. Mol Ther J Am Soc Gene Ther. 2019;27:986\u201398.","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"466_CR40","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1016\/j.ymthe.2017.07.005","volume":"25","author":"S Hainzl","year":"2017","unstructured":"Hainzl S, Peking P, Kocher T, Murauer EM, Larcher F, Del Rio M, et al. COL7A1 editing via CRISPR\/Cas9 in recessive dystrophic epidermolysis bullosa. Mol Ther J Am Soc Gene Ther. 2017;25:2573\u201384.","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"466_CR41","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.omtn.2018.06.008","volume":"12","author":"A Izmiryan","year":"2018","unstructured":"Izmiryan A, Ganier C, Bovolenta M, Schmitt A, Mavilio F, Hovnanian A. Ex\u00a0vivo COL7A1 correction for recessive dystrophic epidermolysis bullosa using CRISPR\/Cas9 and homology-directed repair. Mol Ther Nucleic Acids. 2018;12:554\u201367.","journal-title":"Mol Ther Nucleic Acids."},{"key":"466_CR42","doi-asserted-by":"publisher","first-page":"26846","DOI":"10.1073\/pnas.1907081116","volume":"116","author":"J Jack\u00f3w","year":"2019","unstructured":"Jack\u00f3w J, Guo Z, Hansen C, Abaci HE, Doucet YS, Shin JU, et al. CRISPR\/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells. Proc Natl Acad Sci USA. 2019;116:26846\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1711\u20131721","key":"466_CR43","first-page":"e4","volume":"139","author":"S Takashima","year":"2019","unstructured":"Takashima S, Shinkuma S, Fujita Y, Nomura T, Ujiie H, Natsuga K, et al. Efficient gene reframing therapy for recessive dystrophic epidermolysis bullosa with CRISPR\/Cas9. J Invest Dermatol. 2019;139(1711\u20131721):e4.","journal-title":"J Invest Dermatol."},{"key":"466_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/cells9010112","volume":"9","author":"OP March","year":"2020","unstructured":"March OP, Kocher T, Koller U. Context-dependent strategies for enhanced genome editing of genodermatoses. Cells. 2020;9:112.","journal-title":"Cells."},{"key":"466_CR45","doi-asserted-by":"publisher","first-page":"264ra164","DOI":"10.1126\/scitranslmed.3009342","volume":"6","author":"N Umegaki-Arao","year":"2014","unstructured":"Umegaki-Arao N, Pasmooij AMG, Itoh M, Cerise JE, Guo Z, Levy B, et al. Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa. Sci Transl Med. 2014;6:264ra164.","journal-title":"Sci Transl Med."},{"key":"466_CR46","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0092-8674(00)81894-2","volume":"88","author":"MF Jonkman","year":"1997","unstructured":"Jonkman MF, Scheffer H, Stulp R, Pas HH, Nijenhuis M, Heeres K, et al. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell. 1997;88:543\u201351.","journal-title":"Cell"},{"key":"466_CR47","first-page":"167","volume":"14","author":"AM Pasmooij","year":"2012","unstructured":"Pasmooij AM, Jonkman MF, Uitto J. Revertant mosaicism in heritable skin diseases: mechanisms of natural gene therapy. Discov Med. 2012;14:167\u201379.","journal-title":"Discov Med."},{"key":"466_CR48","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1038\/jid.2014.118","volume":"134","author":"D Kiritsi","year":"2014","unstructured":"Kiritsi D, Garcia M, Brander R, Has C, Meijer R, Jose Escamez M, et al. Mechanisms of natural gene therapy in dystrophic epidermolysis bullosa. J Invest Dermatol. 2014;134:2097\u2013104.","journal-title":"J Invest Dermatol."},{"key":"466_CR49","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1172\/JCI30465","volume":"117","author":"AM Pasmooij","year":"2007","unstructured":"Pasmooij AM, Pas HH, Bolling MC, Jonkman MF. Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3. J Clin Invest. 2007;117:1240\u20138.","journal-title":"J Clin Invest."},{"key":"466_CR50","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/jid.2011.477","volume":"132","author":"AM Pasmooij","year":"2012","unstructured":"Pasmooij AM, Nijenhuis M, Brander R, Jonkman MF. Natural gene therapy may occur in all patients with generalized non-Herlitz junctional epidermolysis bullosa with COL17A1 mutations. J Invest Dermatol. 2012;132:1374\u201383.","journal-title":"J Invest Dermatol."},{"key":"466_CR51","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/bjd.17943","volume":"181","author":"K Twaroski","year":"2019","unstructured":"Twaroski K, Eide C, Riddle MJ, Xia L, Lees CJ, Chen W, et al. Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa. Br J Dermatol. 2019;181:1247\u201353.","journal-title":"Br J Dermatol"},{"key":"466_CR52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jaad.2013.08.052","volume":"70","author":"A Gostynski","year":"2014","unstructured":"Gostynski A, Pasmooij AM, Jonkman MF. Successful therapeutic transplantation of revertant skin in epidermolysis bullosa. J Am Acad Dermatol. 2014;70:98\u2013101.","journal-title":"J Am Acad Dermatol"},{"key":"466_CR53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jaad.2012.04.012","volume":"68","author":"WY Yuen","year":"2013","unstructured":"Yuen WY, Huizinga J, Jonkman MF. Punch grafting of chronic ulcers in patients with laminin-332-deficient, non-Herlitz junctional epidermolysis bullosa. J Am Acad Dermatol. 2013;68:93\u20137 (97 e1-2).","journal-title":"J Am Acad Dermatol."},{"key":"466_CR54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4939-8651-4_2","volume":"1828","author":"M Rodrigues","year":"2018","unstructured":"Rodrigues M, Yokota T. An overview of recent advances and clinical applications of exon skipping and splice modulation for muscular dystrophy and various genetic diseases. Methods Mol Biol Clifton NJ. 2018;1828:31\u201355.","journal-title":"Methods Mol Biol Clifton NJ."},{"key":"466_CR55","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1046\/j.1523-1747.1999.00709.x","volume":"113","author":"JA McGrath","year":"1999","unstructured":"McGrath JA, Ashton GH, Mellerio JE, Salas-Alanis JC, Swensson O, McMillan JR, et al. Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations. J Invest Dermatol. 1999;113:314\u201321.","journal-title":"J Invest Dermatol."},{"key":"466_CR56","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/bjd.14374","volume":"174","author":"C Kowalewski","year":"2016","unstructured":"Kowalewski C, Bremer J, Gostynski A, Wertheim-Tysarowska K, Wozniak K, Bal J, et al. Amelioration of junctional epidermolysis bullosa due to exon skipping. Br J Dermatol. 2016;174:1375\u20139.","journal-title":"Br J Dermatol"},{"key":"466_CR57","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.omtn.2019.09.009","volume":"18","author":"J Bremer","year":"2019","unstructured":"Bremer J, van der Heijden EH, Eichhorn DS, Meijer R, Lemmink HH, Scheffer H, et al. Natural exon skipping sets the stage for exon skipping as therapy for dystrophic epidermolysis bullosa. Mol Ther Nucleic Acids. 2019;18:465\u201375.","journal-title":"Mol Ther Nucleic Acids."},{"key":"466_CR58","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/j.jid.2016.07.029","volume":"136","author":"S Turczynski","year":"2016","unstructured":"Turczynski S, Titeux M, Tonasso L, D\u00e9cha A, Ishida-Yamamoto A, Hovnanian A. Targeted exon skipping restores type VII collagen expression and anchoring fibril formation in an in\u00a0vivo RDEB model. J Invest Dermatol. 2016;136:2387\u201395.","journal-title":"J Invest Dermatol."},{"key":"466_CR59","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1038\/mtna.2016.87","volume":"5","author":"J Bremer","year":"2016","unstructured":"Bremer J, Bornert O, Nystr\u00f6m A, Gostynski A, Jonkman MF, Aartsma-Rus A, et al. Antisense oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa. Mol Ther Nucleic Acids. 2016;5:e379.","journal-title":"Mol Ther Nucleic Acids."},{"key":"466_CR60","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/mt.2016.92","volume":"24","author":"O Bornert","year":"2016","unstructured":"Bornert O, K\u00fchl T, Bremer J, van den Akker PC, Pasmooij AM, Nystr\u00f6m A. Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy. Mol Ther J Am Soc Gene Ther. 2016;24:1302\u201311.","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"466_CR61","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1038\/sj.jid.5700435","volume":"126","author":"M Goto","year":"2006","unstructured":"Goto M, Sawamura D, Nishie W, Sakai K, McMillan JR, Akiyama M, et al. Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients. J Invest Dermatol. 2006;126:2614\u201320.","journal-title":"J Invest Dermatol."},{"key":"466_CR62","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nm1063","volume":"10","author":"DT Woodley","year":"2004","unstructured":"Woodley DT, Keene DR, Atha T, Huang Y, Lipman K, Li W, et al. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med. 2004;10:693\u20135.","journal-title":"Nat Med"},{"key":"466_CR63","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/jid.2013.10","volume":"133","author":"DT Woodley","year":"2013","unstructured":"Woodley DT, Wang X, Amir M, Hwang B, Remington J, Hou Y, et al. Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa. J Invest Dermatol. 2013;133:1910\u20133.","journal-title":"J Invest Dermatol."},{"key":"466_CR64","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.1073\/pnas.1016753108","volume":"108","author":"K Tamai","year":"2011","unstructured":"Tamai K, Yamazaki T, Chino T, Ishii M, Otsuru S, Kikuchi Y, et al. PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci USA. 2011;108:6609\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"466_CR65","doi-asserted-by":"publisher","first-page":"11008","DOI":"10.1038\/srep11008","volume":"5","author":"E Aikawa","year":"2015","unstructured":"Aikawa E, Fujita R, Kikuchi Y, Kaneda Y, Tamai K. Systemic high-mobility group box 1 administration suppresses skin inflammation by inducing an accumulation of PDGFR\u03b1(+) mesenchymal cells from bone marrow. Sci Rep. 2015;5:11008.","journal-title":"Sci Rep."},{"key":"466_CR66","doi-asserted-by":"publisher","first-page":"e0202838","DOI":"10.1371\/journal.pone.0202838","volume":"13","author":"T Kido","year":"2018","unstructured":"Kido T, Miyagawa S, Goto T, Tamai K, Ueno T, Toda K, et al. The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster. PLoS One. 2018;13:e0202838.","journal-title":"PLoS One"},{"key":"466_CR67","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.1016\/j.jid.2017.02.933","volume":"137","author":"T Shimbo","year":"2017","unstructured":"Shimbo T, Yamazaki S, Wang X, Kikuchi Y, Bruckner-Tuderman L, Kaneda Y, et al. 906 Systemic HMGB1 administration ameliorates cutaneous and non-cutaneous manifestations in a dystrophic epidermolysis bullosa model mouse. J Invest Dermatol. 2017;137:S156.","journal-title":"J Invest Dermatol."},{"key":"466_CR68","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature05756","volume":"447","author":"EM Welch","year":"2007","unstructured":"Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87\u201391.","journal-title":"Nature"},{"key":"466_CR69","doi-asserted-by":"publisher","first-page":"e1001593","DOI":"10.1371\/journal.pbio.1001593","volume":"11","author":"SP McElroy","year":"2013","unstructured":"McElroy SP, Nomura T, Torrie LS, Warbrick E, Gartner U, Wood G, et al. A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol. 2013;11:e1001593.","journal-title":"PLoS Biol"},{"key":"466_CR70","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1172\/JCI113325","volume":"81","author":"PD Walker","year":"1988","unstructured":"Walker PD, Shah SV. Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. J Clin Invest. 1988;81:334\u201341.","journal-title":"J Clin Invest."},{"key":"466_CR71","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1750-1172-7-58","volume":"7","author":"S Gonzalez-Hilarion","year":"2012","unstructured":"Gonzalez-Hilarion S, Beghyn T, Jia J, Debreuck N, Berte G, Mamchaoui K, et al. Rescue of nonsense mutations by amlexanox in human cells. Orphanet J Rare Dis. 2012;7:58.","journal-title":"Orphanet J Rare Dis."},{"issue":"1497\u20131505","key":"466_CR72","first-page":"e5","volume":"139","author":"VS Atanasova","year":"2019","unstructured":"Atanasova VS, Russell RJ, Webster TG, Cao Q, Agarwal P, Lim YZ, et al. Thrombospondin-1 is a major activator of TGF-\u03b2 signaling in recessive dystrophic epidermolysis bullosa fibroblasts. J Invest Dermatol. 2019;139(1497\u20131505):e5.","journal-title":"J Invest Dermatol."},{"key":"466_CR73","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1172\/JCI68127","volume":"123","author":"A Nystr\u00f6m","year":"2013","unstructured":"Nystr\u00f6m A, Velati D, Mittapalli VR, Fritsch A, Kern JS, Bruckner-Tuderman L. Collagen VII plays a dual role in wound healing. J Clin Invest. 2013;123:3498\u2013509.","journal-title":"J Clin Invest."},{"key":"466_CR74","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.matbio.2018.01.016","volume":"68\u201369","author":"A Nystr\u00f6m","year":"2018","unstructured":"Nystr\u00f6m A, Bruckner-Tuderman L. Injury- and inflammation-driven skin fibrosis: the paradigm of epidermolysis bullosa. Matrix Biol J Int Soc Matrix Biol. 2018;68\u201369:547\u201360.","journal-title":"Matrix Biol J Int Soc Matrix Biol."},{"key":"466_CR75","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1158\/0008-5472.CAN-11-2996","volume":"72","author":"YZ Ng","year":"2012","unstructured":"Ng YZ, Pourreyron C, Salas-Alanis JC, Dayal JH, Cepeda-Valdes R, Yan W, et al. Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa. Cancer Res. 2012;72:3522\u201334.","journal-title":"Cancer Res"},{"key":"466_CR76","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","volume":"113","author":"Y Shi","year":"2003","unstructured":"Shi Y, Massagu\u00e9 J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685\u2013700.","journal-title":"Cell"},{"key":"466_CR77","doi-asserted-by":"publisher","first-page":"964","DOI":"10.7150\/ijbs.4564","volume":"8","author":"EC Connolly","year":"2012","unstructured":"Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-\u03b2 targeted cancer therapy. Int J Biol Sci. 2012;8:964\u201378.","journal-title":"Int J Biol Sci."},{"key":"466_CR78","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.15252\/emmm.201505061","volume":"7","author":"A Nystr\u00f6m","year":"2015","unstructured":"Nystr\u00f6m A, Thriene K, Mittapalli V, Kern JS, Kiritsi D, Dengjel J, et al. Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. EMBO Mol Med. 2015;7:1211\u201328.","journal-title":"EMBO Mol Med."},{"key":"466_CR79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.matbio.2018.12.001","volume":"81","author":"F Cianfarani","year":"2019","unstructured":"Cianfarani F, De Domenico E, Nystr\u00f6m A, Mastroeni S, Abeni D, Baldini E, et al. Decorin counteracts disease progression in mice with recessive dystrophic epidermolysis bullosa. Matrix Biol J Int Soc Matrix Biol. 2019;81:3\u201316.","journal-title":"Matrix Biol J Int Soc Matrix Biol."},{"key":"466_CR80","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/bjd.14104","volume":"174","author":"JE Mellerio","year":"2016","unstructured":"Mellerio JE, Robertson SJ, Bernardis C, Diem A, Fine JD, George R, et al. Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. Br J Dermatol. 2016;174:56\u201367.","journal-title":"Br J Dermatol"},{"key":"466_CR81","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1056\/NEJMra0707704","volume":"358","author":"F Ciardiello","year":"2008","unstructured":"Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160\u201374.","journal-title":"N Engl J Med"},{"key":"466_CR82","first-page":"448","volume":"17","author":"K Medek","year":"2019","unstructured":"Medek K, Koelblinger P, Koller J, Diem A, Ude-Schoder K, Bauer JW, et al. Wundheilungsst\u00f6rungen w\u00e4hrend der antitumor\u00f6sen Therapie mit Cetuximab bei schwerer generalisierter dystropher Epidermolysis bullosa. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2019;17:448\u201350.","journal-title":"J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG."},{"key":"466_CR83","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000218714","volume":"219","author":"AW Arnold","year":"2009","unstructured":"Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatol Basel Switz. 2009;219:80\u20133.","journal-title":"Dermatol Basel Switz."},{"key":"466_CR84","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/bjd.12272","volume":"169","author":"M Kim","year":"2013","unstructured":"Kim M, Li M, Intong LRA, Tran K, Melbourne W, Marucci D, et al. Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma. Br J Dermatol. 2013;169:208\u201310.","journal-title":"Br J Dermatol"},{"key":"466_CR85","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/jdv.15835","volume":"34","author":"A Reimer","year":"2020","unstructured":"Reimer A, Lu S, He Y, Bruckner-Tuderman L, Technau-Hafsi K, Meiss F, et al. Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. J Eur Acad Dermatol Venereol JEADV. 2020;34:e1\u20133.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"key":"466_CR86","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13023-019-1262-7","volume":"14","author":"A Diociaiuti","year":"2019","unstructured":"Diociaiuti A, Steinke H, Nystr\u00f6m A, Schwieger-Briel A, Meiss F, Pfannenberg C, et al. EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2019;14:278.","journal-title":"Orphanet J Rare Dis."},{"key":"466_CR87","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367.","journal-title":"N Engl J Med"},{"key":"466_CR88","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379:341\u201351.","journal-title":"N Engl J Med"},{"key":"466_CR89","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2003.08.008","volume":"50","author":"JD Fine","year":"2004","unstructured":"Fine JD, Johnson LB, Weiner M, Stein A, Suchindran C. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a phase 1 trial of systemic isotretinoin. J Am Acad Dermatol. 2004;50:563\u201371.","journal-title":"J Am Acad Dermatol"},{"key":"466_CR90","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1158\/1078-0432.CCR-18-2661","volume":"25","author":"VS Atanasova","year":"2019","unstructured":"Atanasova VS, Pourreyron C, Farshchian M, Lawler M, Brown CA, Watt SA, et al. Identification of rigosertib for the treatment of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25:3384\u201391.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"466_CR91","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/exd.13979","volume":"28","author":"C Prodinger","year":"2019","unstructured":"Prodinger C, Reichelt J, Bauer JW, Laimer M. Epidermolysis bullosa: advances in research and treatment. Exp Dermatol. 2019;28:1176\u201389.","journal-title":"Exp Dermatol"},{"key":"466_CR92","doi-asserted-by":"publisher","first-page":"e126243","DOI":"10.1172\/jci.insight.126243","volume":"4","author":"SM Lwin","year":"2019","unstructured":"Lwin SM, Syed F, Di W-L, Kadiyirire T, Liu L, Guy A, et al. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. JCI Insight. 2019;4:e126243.","journal-title":"JCI Insight."},{"key":"466_CR93","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3390\/ijms19040946","volume":"19","author":"MJ Osborn","year":"2018","unstructured":"Osborn MJ, Lees CJ, McElroy AN, Merkel SC, Eide CR, Mathews W, et al. CRISPR\/Cas9-based cellular engineering for targeted gene overexpression. Int J Mol Sci. 2018;19:946.","journal-title":"Int J Mol Sci."},{"key":"466_CR94","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/npjregenmed.2016.14","volume":"1","author":"BR Webber","year":"2016","unstructured":"Webber BR, Osborn MJ, McElroy AN, Twaroski K, Lonetree C-L, DeFeo AP, et al. CRISPR\/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. NPJ Regen Med. 2016;1:16014.","journal-title":"NPJ Regen Med."},{"key":"466_CR95","doi-asserted-by":"publisher","first-page":"5676","DOI":"10.1073\/pnas.1512028113","volume":"113","author":"S Shinkuma","year":"2016","unstructured":"Shinkuma S, Guo Z, Christiano AM. Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa. Proc Natl Acad Sci USA. 2016;113:5676\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"key":"466_CR96","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1073\/pnas.1614775114","volume":"114","author":"W Wu","year":"2017","unstructured":"Wu W, Lu Z, Li F, Wang W, Qian N, Duan J, et al. Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model. Proc Natl Acad Sci USA. 2017;114:1660\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"466_CR97","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1016\/j.ymthe.2018.07.024","volume":"26","author":"D Benati","year":"2018","unstructured":"Benati D, Miselli F, Cocchiarella F, Patrizi C, Carretero M, Baldassarri S, et al. CRISPR\/Cas9-mediated in situ correction of LAMB3 gene in keratinocytes derived from a junctional epidermolysis bullosa patient. Mol Ther J Am Soc Gene Ther. 2018;26:2592\u2013603.","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"466_CR98","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/gt.2016.57","volume":"23","author":"B Tockner","year":"2016","unstructured":"Tockner B, Kocher T, Hainzl S, Reichelt J, Bauer JW, Koller U, et al. Construction and validation of an RNA trans-splicing molecule suitable to repair a large number of COL7A1 mutations. Gene Ther. 2016;23:775\u201384.","journal-title":"Gene Ther"},{"key":"466_CR99","doi-asserted-by":"publisher","first-page":"10259","DOI":"10.1093\/nar\/gkx669","volume":"45","author":"P Peking","year":"2017","unstructured":"Peking P, Koller U, Duarte B, Murillas R, Wolf S, Maetzig T, et al. An RNA-targeted therapy for dystrophic epidermolysis bullosa. Nucleic Acids Res. 2017;45:10259\u201369.","journal-title":"Nucleic Acids Res"},{"key":"466_CR100","doi-asserted-by":"crossref","unstructured":"Mellerio J, Uitto J. Meeting report: The first global congress on epidermolysis bullosa, EB2020 -Toward treatment and cure. J Invest Dermatol (in press).","DOI":"10.1016\/j.jid.2020.05.078"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-020-00466-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-020-00466-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-020-00466-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T23:34:16Z","timestamp":1619134456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-020-00466-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["466"],"URL":"https:\/\/doi.org\/10.1007\/s40291-020-00466-7","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"23 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"C.H. was on the advisory board of Castle Creek Biosciences Inc. and A.P.S. owns stock in Krystal Biotech, Inc. J.U. has no conflicts of interest. That are Is Castle Creek Pharmaceuticals the same as the \u201aCastle Creek Biosciences\u2018 mentioned in Table\u00a01 and Sect. 4.1? If so, which name should be used for consistency? directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}